Who
Adam Savitz
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Alto Neuroscience.
In numbers
- Trades disclosed
- 20
- Buys
- 3
- Sells
- 0
- Bought
- $463K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Feb 2024
- Last trade
- 11 Feb 2026
- Last filed
- 13 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Feb 2026filed 13 Feb 2026 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —124,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —124,000 at $0.00 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,481 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —22,481 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,008 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —33,008 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,645 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —123,645 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —73,000 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —73,000 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,000 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —76,000 | filing |
| 5 Feb 2025filed 7 Feb 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,000 at $0.00 | filing |
| 10 Jul 2024filed 11 Jul 2024 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Bought | $39K2,931 at $13.22 | filing |
| 9 Jul 2024filed 11 Jul 2024 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Bought | $134K10,681 at $12.53 | filing |
| 9 Jul 2024filed 11 Jul 2024 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Bought | $18K1,388 at $13.15 | filing |
| 1 Mar 2024filed 5 Mar 2024 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —73,000 at $0.00 | filing |
| 6 Feb 2024filed 7 Feb 2024 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code C | —16,666 at $0.00 | filing |
| 6 Feb 2024filed 7 Feb 2024 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code C | —7,851 | filing |
| 6 Feb 2024filed 7 Feb 2024 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Bought | $272K17,000 at $16.00 | filing |
News
No headline names them, or the companies they trade most, lately.